MARKET

ATHA

ATHA

Athira Pharma, Inc.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

16.25
+0.23
+1.44%
Closed 16:00 09/25 EDT
OPEN
16.01
PREV CLOSE
16.02
HIGH
16.42
LOW
16.00
VOLUME
268.98K
TURNOVER
--
52 WEEK HIGH
20.42
52 WEEK LOW
15.79
MARKET CAP
468.24M
P/E (TTM)
-80.8860
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
The Daily Biotech Pulse: Novavax Advances Vaccine, Marinus Gets Nod For Late-Stage Study, 3 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 24)
Benzinga · 2d ago
The Daily Biotech Pulse: Gilead's $7.25B Debt Offering, Lexicon Deleverages, Taysha Gene Therapies Prices IPO
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 23)
Benzinga · 3d ago
Athira Pharma Announces Closing of Initial Public Offering
SEATTLE, Sept. 22, 2020 (GLOBE NEWSWIRE) -- Athira Pharma, Inc., (Nasdaq: ATHA) (“Athira”), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, today announced the closing of its initial public offering of 12,000,000
GlobeNewswire · 5d ago
The Daily Biotech Pulse: Legal Relief For Evolus, Fulgent to Join S&P SmallCap 600, AIM ImmunoTech's Positive Cancer Drug Readout
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 21)
Benzinga · 5d ago
U.S. IPO Weekly Recap: Snowflake's IPO Breaks Records In A Diverse 15-IPO Week
In the busiest week yet for the 2020 IPO market, 15 IPOs raised $8.7 billion.Snowflake took the spotlight, completing the largest software IPO ever and bagging the biggest billion-dollar pop in two decades.Eight SPACs joined the week's diverse group of IPOs.
Seekingalpha · 09/19 13:54
Athira Pharma estimated to open +29% above IPO
Athira Pharma (ATHA) hints to open at $22 vs. IPO price of $17.Pricing was at the high end of the target range of $15-$17.Offering was upsized from 10M shares to
Seekingalpha · 09/18 15:00
Athira Upsizes IPO, Looks To Raise Over $204M
Athira Pharma Inc. (NASDAQ: ATHA) on Thursday upsized its initial public offering plans over what it earlier reported in a filing with the Securities and Exchange Commission.
Benzinga · 09/18 08:17
Athira Pharma prices upsized IPO at $17
Athira Pharma (ATHA) has priced its upsised IPO of 12M (from 10M) common shares at $17.00/share, for expected gross proceeds of $204M.Athira is a biopharmaceutical company focused on developing small
Seekingalpha · 09/18 05:28
More
Forecast
EPSBVPSCFPS
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ATHA. Analyze the recent business situations of Athira Pharma, Inc. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+3.04%
Pharmaceuticals & Medical Research
+1.58%
Key Executives
President/Chief Executive Officer
Leen Kawas
Chief Financial Officer/Secretary/Primary Contact
Glenn Mileson
Chief Operating Officer
Mark Litton
General Counsel
Christina Thomson
Other
Han Moebius
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About ATHA
Athira Pharma, Inc. is a clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration. The Company’s pipeline is built from its drug discovery platform (ATH) platform, and consists of a series of small molecules that are designed to target either the central nervous system (CNS), by crossing the blood brain barrier (BBB), or the peripheral nervous system. The ATH platform utilizes proprietary technology to target and enhance the activity of a vital neuronal growth factor that promotes neuronal health and regeneration. The Company is developing ATH-1017, for the treatment of neurodegenerative disorders, with an initial focus on Alzheimer’s disease (AD). ATH-1017 is designed to enhance neuronal health and promote regeneration, thereby improving symptoms in cognitively impaired subjects.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Athira Pharma Inc stock information, including NASDAQ:ATHA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ATHA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ATHA stock methods without spending real money on the virtual paper trading platform.